ImmunityBio, Inc.
IBRX
Pozycja w akcjach
#2196
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Cena akcji
$8.77
Ostatnia synchronizacja: 2026-10-20
Kapitalizacja rynkowa
$9.29B
Zmiana (1 dzień)
4.12%
Zmiana (1 rok)
259.29%
Kraj
US
Handel ImmunityBio, Inc. (IBRX)
Kategoria
Healthcare
Przychody dla ImmunityBio, Inc. (IBRX)
Przychody w Jun 2026 TTM: $165.79M
Według najnowszych raportów finansowych ImmunityBio, Inc., obecny przychód firmy (TTM) wynosi $165.79M. W roku 2023 firma osiągnęła przychód w wysokości $622.00K wzrost w porównaniu do przychodu z roku 2022, który wynosił $240.00K. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy ImmunityBio, Inc. od 2013 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $165.79M | 1,024.39% |
| 2024 | $14.75M | 2,270.58% |
| 2023 | $622.00K | 159.17% |
| 2022 | $240.00K | -74.30% |
| 2021 | $934.00K | 54.38% |
| 2020 | $605.00K | 1,306.98% |
| 2019 | $43.00K | -8.51% |
| 2018 | $47.00K | 4.44% |
| 2017 | $45.00K | 2.27% |
| 2016 | $44.00K | -81.36% |
| 2015 | $236.00K | -63.18% |
| 2014 | $641.00K | 6.83% |
| 2013 | $600.00K | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $12.62B | 7,514.54% |
US
|
|
| $2.23B | 1,243.85% |
US
|
|
| $15.74B | 9,396.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 3,531.83% |
NL
|
